Earnings Call · Q2 FY2022·2022-08-12

Q2 22EPS -100.00%*·Rev n/aQ1 22EPS -100.00%*·Rev n/aQ4 21EPS -78.95%·Rev n/aQ3 21EPS -84.62%·Rev n/a⚠ consensus missing

Eton Pharmaceuticals, Inc. ETON

David Krempa — Senior Vice President of Business Development

Sean Brynjelsen — Chief Executive Officer

James Gruber — Chief Financial Officer

+2.4%1d on move date+2.4% vs SPY3d−8.8%5d−17.3%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more ETON calls or request research access.

More ETON calls Browse calls Request research access